专利检索 ap:("Metabolon, Inc.") AND inv:"LAWTON, Kay" 第 1 页

1.

发明公开
BIOMARKERS FOR PRE-DIABETES, CARDIOVASCULAR DISEASES, AND OTHER METABOLIC-SYNDROME RELATED DISORDERS AND METHODS USING THE SAME 有权
标题翻译：生物标记FOR USE糖尿病前兆与方法

公开(公告)号：EP2164977A2

公开(公告)日：2010-03-24

申请号：EP08780229.4

申请日：2008-07-17

申请人： Metabolon Inc.

发明人： HU, Yun, Fu , CHIRILA, Costel , ALEXANDER, Danny , MILBURN, Michael , MITCHELL, Matthew, W. , GALL, Walter , LAWTON, Kay

IPC分类号： C12Q1/00

CPC分类号： G01N33/5308 , G01N33/483 , G01N33/487 , G01N33/5091 , G01N33/6893 , G01N2800/04 , G01N2800/042 , G01N2800/044 , G01N2800/32 , G01N2800/50 , G01N2800/52 , G01N2800/56

摘要： Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy.

2.

发明授权
BIOMARKERS FOR PRE-DIABETES AND METHODS USING THE SAME 有权
标题翻译：生物标记FOR USE糖尿病前兆与方法

公开(公告)号：EP2164977B1

公开(公告)日：2013-10-30

申请号：EP08780229.4

申请日：2008-07-17

申请人： Metabolon, Inc.

发明人： HU, Yun, Fu , CHIRILA, Costel , ALEXANDER, Danny , MILBURN, Michael , MITCHELL, Matthew, W. , GALL, Walter , LAWTON, Kay

IPC分类号： C12Q1/00

CPC分类号： G01N33/5308 , G01N33/483 , G01N33/487 , G01N33/5091 , G01N33/6893 , G01N2800/04 , G01N2800/042 , G01N2800/044 , G01N2800/32 , G01N2800/50 , G01N2800/52 , G01N2800/56

摘要： Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy.